GO
Loading...

Amgen Inc

More

  • NEW YORK, Jan 26- A new wave of experimental cancer drugs that directly recruit the immune system's powerful T cells are proving to be immensely effective weapons against tumors, potentially transforming the $100 billion global market for drugs that fight the disease. But top oncology researchers are concerned about the two emerging technologies, citing...

  • Final Glance: Biotechnology companies Friday, 23 Jan 2015 | 6:04 PM ET

    Amgen Inc. rose$. 24 or. 2 percent, to $159.81. Biogen Idec rose $3.88 or 1.1 percent, to $357.53. Celgene Corp. rose$. 18 or. 1 percent, to $123.89.

  • Midday Glance: Biotechnology companies Friday, 23 Jan 2015 | 1:31 PM ET

    Amgen Inc. fell$. 45 or. 3 percent, to $159.12. Biogen Idec rose $4.60 or 1.3 percent, to $358.25. Celgene Corp. rose$. 04 or percent, to $123.75.

  • Early Glance: Biotechnology companies Friday, 23 Jan 2015 | 11:24 AM ET

    Amgen Inc. fell$. 51 or. 3 percent, to $159.07. Biogen Idec rose $2.25 or. 6 percent, to $355.90. Celgene Corp. fell$. 73 or. 6 percent, to $122.98.

  • Final Glance: Biotechnology companies Thursday, 22 Jan 2015 | 6:05 PM ET

    Amgen Inc. rose $2.19 or 1.4 percent, to $159.57. Biogen Idec fell $8.18 or 2.3 percent, to $353.65. Celgene Corp. rose $1.49 or 1.2 percent, to $123.71.

  • Midday Glance: Biotechnology companies Thursday, 22 Jan 2015 | 1:29 PM ET

    Amgen Inc. rose$. 42 or. 3 percent, to $157.80. Biogen Idec fell $10.37 or 2.9 percent, to $351.46. Celgene Corp. fell$. 20 or. 2 percent, to $122.02.

  • This measure says stocks are really cheap…maybe Thursday, 22 Jan 2015 | 12:26 PM ET
    Traders on the floor of the New York Stock Exchange.

    One valuation measure has sparked a debate among strategists as to whether the stock market is really, really cheap.

  • Early Glance: Biotechnology companies Thursday, 22 Jan 2015 | 12:09 PM ET

    Amgen Inc. fell $2.08 or 1.3 percent, to $155.30. Biogen Idec fell $10.44 or 2.9 percent, to $351.39. Celgene Corp. fell $1.14 or. 9 percent, to $121.08.

  • Final Glance: Biotechnology companies Wednesday, 21 Jan 2015 | 6:01 PM ET

    Amgen Inc. fell$. 22 or. 1 percent, to $157.38. Biogen Idec fell $1.46 or. 4 percent, to $361.83. Celgene Corp. fell $1.03 or. 8 percent, to $122.22.

  • Meet Morningstar's fund managers of the year Wednesday, 21 Jan 2015 | 5:42 PM ET

    Here are the fund managers Morningstar considers the best of the best.

  • Jan 21- The U.S. Food and Drug Administration approved Novartis AG's injectable drug, Cosentyx, to treat adults with a moderate to severe skin disease called plaque psoriasis. Eli Lilly and Co will begin marketing its IL-17 inhibitor ixekizumab in the first half of 2015, while Amgen Inc and AstraZeneca Plc's brodalumab reported positive results from a...

  • Midday Glance: Biotechnology companies Wednesday, 21 Jan 2015 | 1:22 PM ET

    Amgen Inc. rose$. 05 or percent, to $157.65. Biogen Idec rose$. 13 or percent, to $363.41. Celgene Corp. fell$. 83 or. 7 percent, to $122.42.

  • Early Glance: Biotechnology companies Wednesday, 21 Jan 2015 | 10:45 AM ET

    Amgen Inc. fell$. 68 or. 4 percent, to $156.93. Biogen Idec fell $2.04 or. 6 percent, to $361.24. Celgene Corp. fell$. 82 or. 7 percent, to $122.43.

  • Final Glance: Biotechnology companies Tuesday, 20 Jan 2015 | 6:35 PM ET

    Amgen Inc. fell$. 83 or. 5 percent, to $157.60. Biogen Idec rose $10.53 or 3.0 percent, to $363.28. Celgene Corp. rose $1.44 or 1.2 percent, to $123.25.

  • Midday Glance: Biotechnology companies Tuesday, 20 Jan 2015 | 1:33 PM ET

    Amgen Inc. fell $2.21 or 1.4 percent, to $156.22. Biogen Idec rose $3.65 or 1.0 percent, to $356.40. Celgene Corp. fell$. 30 or. 2 percent, to $121.51.

  • Early Glance: Biotechnology companies Tuesday, 20 Jan 2015 | 10:33 AM ET

    Amgen Inc. fell $2.17 or 1.4 percent, to $156.26. Biogen Idec fell $1.29 or. 4 percent, to $351.46. Celgene Corp. fell$. 73 or. 6 percent, to $121.08.

  • Benefits firms shouldn't play drug favorites: CEO Tuesday, 20 Jan 2015 | 10:00 AM ET

    Regeneron Pharmaceuticals CEO Dr. Leonard Schleifer told CNBC on Tuesday that benefits companies should not try to practice medicine.

  • SAN FRANCISCO, Jan 15- The world's biggest drugmakers face a new reality when it comes to U.S. pricing for their products as insurers use aggressive tactics to extract steep price discounts, even for the newest medications. Big Pharma executives acknowledged the depth of change this week during public presentations and interviews with Reuters at the J.P....

  • Jan 9- An experimental drug from Sanofi SA and Regeneron Pharmaceuticals was found to be effective in lowering "bad" cholesterol even when administered once every four weeks, instead of every two weeks. Sanofi SA and Regeneron are in a fierce race with Pfizer and Amgen Inc to bring their PCSK9 inhibitor to the market, which is expected to be worth billions if these...

  • Jan 7- A panel to the U.S. Food and Drug Administration unanimously backed the approval of Novartis AG's copy of Amgen Inc's blockbuster cancer drug Neupogen, setting the stage for the regulator's first approval of a biosimilar. The biosimilar could be priced at the same level as Neupogen, but cost to insurers and consumers would be lower, Novartis executives...